Related Articles
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non‑small cell lung cancer
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review)
High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
Implication of PD‑L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PD‑1 blockades: A retrospective exploratory study